A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.
Noura J ChoudhuryW Victoria LaiAlex MakhninGlenn HellerJuliana EngBob T LiIsabel R PreeshagulFernando C SantiniMichael D OffinKenneth NgPaul K PaikChristina LarsenMichelle S GinsbergYvonne LauXinyuan ZhangMarina K BaineNatasha RekhtmanCharles M RudinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Combination valemetostat and irinotecan was not tolerated but demonstrated efficacy in recurrent SCLC. Valemetostat, combined with agents without overlapping toxicity, warrants further investigation in SCLC.